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Summary
Background: Prenatal environment has been shown to influence child's risk of ato-
pic diseases. Laboratory‐confirmed data about the role of maternal infections during
pregnancy is scarce.
Objective: The aim of this study was to determine the associations between sero-
logically confirmed maternal infections during pregnancy and atopic disease in the
offspring.
Methods: This was a nested case‐control study within a prospective birth cohort
study. Altogether 202 atopic case children and 333 matched non‐atopic control chil-
dren were included. Atopic outcome was defined as having an atopic disease and
IgE sensitization by the age of 5 years. We analysed serologically acute enterovirus
(EV), influenza virus A (IAV) and Mycoplasma pneumoniae (M. pneumoniae) infections
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during pregnancy, and mother's seropositivity against human cytomegalovirus (CMV)
and Helicobacter pylori.
Results: Maternal EV infection during pregnancy was inversely associated with ato-
pic outcome in the offspring (odds ratio 0.43; 95% confidence interval: 0.23‐0.80,
P = 0.008). Acute IAV or M. pneumoniae infections or seropositivity against CMV or
Helicobacter pylori were not associated with the atopic outcome.
Conclusions and Clinical Relevance: Our results suggest that maternal EV infections
during pregnancy are inversely associated with atopic disease in the offspring. Our
finding provides further support to the previous studies suggesting an important
role of the in utero environment in the development of atopic diseases.
1 | INTRODUCTION
Genetic factors regulate the susceptibility to atopic diseases but the
environment has a significant impact on the disease development.
Atopic diseases usually manifest in childhood stressing the impor-
tance of environmental factors present in very early life.1 Accord-
ingly, extensive data suggest that a variety of environmental
exposures in early childhood can influence the development of ato-
pic diseases.2 Postnatal microbial infections have been among the
most studied factors and several reports have suggested a modula-
tion of the risk of atopic diseases by childhood infections.3-11
Recently, it has become increasingly evident that already the in
utero environment may be important in the development of atopic
diseases.2 A number of prenatal factors, for example, maternal smok-
ing,12 adverse life events13 and pre‐pregnancy overweight14 have
been associated with increased risk of atopic diseases in the off-
spring. In contrast, maternal exposure to farming environment has
been shown to protect the child from atopy.15-17 These findings,
consistent with the framework of hygiene hypothesis, raise the
question about the role of prenatal microbial infections in atopy.
The majority of previous data on prenatal infections are derived from
questionnaire‐based studies, most of which report an increased risk of
atopic disease in children born to mothers with febrile or flu‐like infec-
tions during pregnancy.18 However, questionnaire‐based studies do not
enable the identification of culprit microbes and they may be affected by
recall bias. Applying laboratory assay‐based methods can overcome these
shortcomings but such studies are scarce.19-22 Maternal gastrointestinal
helminth infections have been reported both to inversely associate with
eczema in the offspring20 and not to associate with atopy.19 Intrauterine
bacterial growth at birth as well as chorioamnionitis has been shown to
increase the risk of asthma in the offspring.21,23
We wanted to investigate whether laboratory‐confirmed prenatal
infections are associated with atopic outcome in the offspring. In
addition, we aimed to determine whether microbes with different
infectious and immunological reaction patterns differ in their effect.
Five microbes, featuring gastrointestinal and respiratory pathogens,
as well as microbes causing acute and chronic infections were
included in the current study.
Enteroviruses (EV) can replicate in the gastrointestinal tract, and
they have been linked to atopy in some studies6-8 but not all.4,5 Heli-
cobacter pylori (H. pylori), causing chronic gastric infections and
inflammation, and also considered to be a marker of the general
hygiene level, has been shown to associate with atopy.24 Influenza
virus A (IAV) causes a strong acute systemic infection, whereas cyto-
megalovirus (CMV) persists as a lifelong latent infection. Mycoplasma
pneumoniae (M. pneumoniae) in turn causes often subclinical, chronic
lower respiratory tract infections. We analysed acute gestational EV,
IAV and M. pneumoniae infections by serology from paired serum
samples taken during pregnancy. We estimated the incidence of
acute H. pylori and CMV infections during pregnancy to be very low
in the Finnish population and therefore chose to analyse the pres-
ence of these chronic/latent infections from a single serum sample.
2 | MATERIALS AND METHODS
2.1 | Subjects
The study cohort was derived from the prospective Type 1 Diabetes
Prediction and Prevention (DIPP) study in Finland.25 In the DIPP
study, newborn infants with HLA conferred susceptibility to type 1
diabetes are invited to enter a prospective follow‐up with visits at
the study clinic every 3‐12 months. At each visit, children undergo a
comprehensive interview and clinical examination. Biological samples,
including venous blood samples, are collected according to the study
protocol.
In the present study, we first searched the DIPP database for
children fulfilling the atopic outcome criteria applied: Diagnosis of
bronchial asthma, atopic dermatitis and/or allergic rhinitis and a posi-
tive serum IgE level against aeroallergens at the age of 5 years. Alto-
gether, 202 atopic case children were identified. They were born
between June 1996 and September 2004 in the regions of Tampere
and Oulu cities. Next, we selected 1‐2 non‐atopic control children
for each case child having neither specific IgE against aeroallergens
nor diagnosis of any atopic disease (n = 333). Case and control chil-
dren were matched for gender, region of birth, time of birth (±
3 months) and type 1 diabetes‐related HLA‐DQB1 alleles. In total,
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128 (63%) case children and 207 (62%) control children were boys.
The mean age difference between cases and controls was 45 days
(SD 34 days, range 0‐91 days), and the percentages of case and con-
trol children born each season of the year were equal. Altogether,
9% of children carried the HLA‐DQB1 *02/*03:02 genotype and
91% had the *03:02/x genotype with x referring to other alleles than
*02, *03:01 or *06:02.
Paired serum samples were available from each mother of partic-
ipating children. First sample was taken in prenatal clinics at the end
of the first trimester of pregnancy as a part of a national screening
for infectious diseases. These samples are stored in the nationwide
Finnish Maternity Cohort biobank. The second sample was cord
blood serum from the newborn infant collected according to DIPP
study protocol. The Finnish Maternity Cohort Steering Group at the
National Institute for Health and Welfare approved the use of bio-
bank samples in this study. The DIPP study protocol has been
approved by the ethical committees of the participating university
hospitals (ETL 97193M), and parents have given written informed
consent.
2.2 | IgE antibodies
IgE antibodies against a mixture of common aeroallergens were anal-
ysed from the serum samples taken at the age of 5 years with
ImmunoCAP® enzyme immunoassay (Phadia AB, Uppsala, Sweden).
The multi‐allergen test used (Phadiatop®, Phadia AB, Uppsala, Swe-
den) contains allergens of common pollens, moulds and animals.
Values of ≥0.35 kU/L were considered positive.
2.3 | Microbial analyses
IgG class antibodies against EV, IAV, H. pylori and M. pneumoniae
were measured by applying enzyme immune assays (EIA). IgG class
antibodies against CMV were measured either by applying EIA or by
chemiluminescent immunoassay (CLIA). For CMV, two different
assays were used due to changes in laboratory equipment during the
study period but each case‐control pair was always analysed with
the same method.
Enterovirus, IAV and M. pneumoniae antibodies were analysed
from both first trimester serum samples and cord blood, H. pylori
antibodies from cord blood and CMV antibodies from first trimester
serum samples (n = 146) or cord blood (n = 381), whichever was
available. Samples from case‐control pairs and related first trimester
and cord blood samples were analysed in parallel in the same test
run. All analyses were carried out blind to clinical information.
The assay for EV antibodies employed a synthetic EV peptide
that carries an immunodominant epitope of the viral VP1 protein (se-
quence KEVPALTAVETGAT‐C) as an antigen, as described.26 This
epitope is highly conserved among EVs detecting antibodies against
a wide range of different EV types. For IAV, we used influenza A
virus strain Beijing (BA1231VS, Virion Serion, Würzburg, Germany)
as an antigen, as previously described.27 In brief, microtiter plates
(Nunc Immuno™ plate, Maxisorb, Thermo Fisher Scientific, Waltham,
MA, USA) were coated by the antigens at concentrations 1 μg/mL
for EV and 3 μg/mL for IAV in carbonate buffer (pH 9.4). Serum sam-
ples were analysed diluted 1:1000 in PBS supplemented with 1%
bovine serum albumin, 2% NaCl and 0.05% Tween 20. Serial dilu-
tions for strong positive serum samples were used to reach standard
curve range. Binding of antibodies was documented by using peroxi-
dase‐conjugated anti‐human IgG (P214, Dako, Glostrup, Denmark)
and measuring the absorbance at 490 nm. The results were given in
enzyme immunoassay units (EIU) with reference to negative and
positive control samples. An EIU value of 15 was applied as a cut‐off
level for seropositivity as described.26
Antibodies against H. pylori (Enzygnost® Anti‐Helicobacter pylori/
IgG, Siemens, Marburg, Germany) and antibodies against M. pneumo-
niae (Mycoplasma pneumonia IgG, Labsystems Diagnostics Ltd, Hel-
sinki, Finland) were measured using commercial kits according to the
manufacturers’ instructions. For the analysis of antibodies against
CMV from the first trimester samples, we applied Enzygnost® Anti‐
CMV/IgG EIA kit (Siemens), and for cord blood samples, we used
LIAISON® CMV IgG II CLIA (DiaSorin S.p.A., Saluggia (VC), Italy)
according to the manufacturers’ instructions. We used Siemens BEP
III (Siemens) for processing and calculation of the antibody levels for
the EIAs and LIAISON® XL (DiaSorin S.p.A.) for CLIA.
2.4 | Definition of acute infection
According to the manufacturer's instructions, we defined an acute
M. pneumoniae infection as a 1.6‐fold or higher increase in antibody
level between the maternal first trimester sample and the child's
cord blood sample. For cohesion, we applied the same criteria also
for EV and IAV to indicate an acute infection during pregnancy.
2.5 | Statistical methods
We applied conditional logistic regression analysis to determine the
association between an acute infection during pregnancy (EV, IAV,
M. pneumoniae) or seropositivity (CMV, H. pylori) and atopic disease.
The results are presented as odds ratios (OR) and 95% confidence
intervals (CI) for atopic disease.
Demographic factors are presented in Table 1. We applied condi-
tional regression analysis to estimate the individual association of
each variable with atopic outcome. When an association was
observed, conditional regression analysis was applied to adjust for
these factors. If a value was missing from the case child or all con-
trols in the case‐control group, that case‐control pair/triplet was
excluded from the analyses.
We applied the Bonferroni correction to counteract the problem
of multiple comparisons. As we analysed the association between
acute infection during pregnancy and atopic disease for three
microbes, the Bonferroni correction to control type I error was justi-
fied. After applying the Bonferroni correction, that is, dividing
P = 0.05 by 3, P‐values < 0.017 were regarded as statistically signifi-
cant. Similarly, as seropositivity in a single serum sample was anal-
ysed for two microbes, after applying Bonferroni correction, P‐
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values < 0.025 were statistically significant. Unadjusted P‐values are
presented in the text.
Analyses were performed by using R version 3.3.3 (2017‐03‐06,
The R Foundation for Statistical Computing, https://www.R-project.
org).
3 | RESULTS
Out of the 202 case children, 52 (26%) had asthma, 126 (62%) had
atopic eczema and/or allergic rhinitis, and 24 (12%) had both asthma
and eczema/rhinitis. Specific IgE values varied between 0.36 and
101 kU/L (mean 22.9, median 11). Demographics and their associa-
tions with atopic outcome are presented in Table 1.
A gestational EV infection was observed in 17 (8%) mothers of
the case children and in 53 (16%) mothers of the control children
(Figure 1). M. pneumoniae infection was detected in 14 (7%) vs 37
(11%), and IAV in 26 (13%) vs 43 (13%) mothers of case and control
children, respectively. Seropositivity against CMV was observed in
148 (74%) vs 243 (74%), and H. pylori in 14 (7%) vs 37 (11%) moth-
ers of the case and control children, respectively.
Maternal EV infection during pregnancy was inversely associated
with atopic outcome in the offspring (OR: 0.43; 95% CI: 0.23‐0.80;
P = 0.008). The result remained statistically significant after adjusting
for the relevant confounding factors, that is, older siblings and furry
pets (OR: 0.43; 95% CI: 0.23‐0.81; P = 0.009) (Figure 2). Maternal
IAV or M. pneumoniae infections during pregnancy did not associate
with atopic outcome (OR: 1.05; 95% CI: 0.62‐1.79 and OR: 0.65;
95% CI: 0.34‐1.22, respectively). When all the three microbes were
analysed together, 49 (24%) case mothers and 115 (35%) control
mothers had experienced at least one acute infection during preg-
nancy (OR: 0.60; 95% CI: 0.39‐0.90; P = 0.015).
Maternal seropositivity against CMV or H. pylori was not associ-
ated with atopic outcome in the offspring (OR: 0.99; 95% CI: 0.66‐
1.47 and OR: 0.58; 95% CI: 0.30‐1.12, respectively).
4 | DISCUSSION
The current study suggests that maternal EV infections during preg-
nancy are inversely associated with atopic disease in the offspring.
To our knowledge, EVs or other microbes included have not been
studied in a similar laboratory‐based study setting previously.
We did not find any association between prenatal IAV and
M. pneumoniae infections and atopic outcome. One reason may lie in
the route of infection; IAV and M. pneumoniae are respiratory
microbes, whereas EVs can replicate also in the gut. There are indi-
cations that exposures to enteric pathogens might be particularly
important in the development of atopy and they have been reported
to inversely associate with atopy in some studies28,29 but not in
all.3,11 Our group has previously observed an inverse association
between neutralizing antibodies against echoviruses, belonging to
the enterovirus genus, and atopy.6,7 A recent study showed reduced
anti‐echovirus 30 antibody titres in asthmatic children as compared
with non‐asthmatics,8 which was contrary to a previous rhinovirus
antibody finding.9 In addition, some EVs replicate for relatively long
periods in the gut‐associated lymphoid tissue that is believed to be
important in maintaining immunological tolerance, and EV infections
have been shown to associate with tolerogenic immune responses,
for example, production of IL‐10.30
TABLE 1 Frequencies of potential confounders in case and control children and associations with the study outcome
Case
n = 202 (%)
Control
n = 333 (%) OR (95% CI) P value
Older siblings (yes) 95 (47) 201 (60) 0.60 (0.42‐0.86) 0.006
Furry pets (yes) 58 (29) 146 (44) 0.53 (0.36‐0.78) 0.001
Smoking in pregnancy (yes) 17 (9) 28 (8) 1.00 (0.53‐1.89) 1.00
Maternal education
No secondary 50 (27) 98 (31) ref
Lower secondary 91 (48) 151 (48) 1.01 (0.65‐1.59) 0.96
Higher secondary 48 (25) 63 (20) 1.26 (0.76‐2.11) 0.37
Paternal education
No secondary 86 (46) 144 (48) ref
Lower secondary 46 (25) 88 (30) 0.92 (0.59‐1.44) 0.71
Higher secondary 56 (30) 66 (22) 1.34 (0.85‐2.11) 0.21
Duration of pregnancyab 280 (224‐300) 280 (209‐300) 1.01 (0.99‐1.02) 0.53
Birth weightac 3650 (1910‐4830) 3610 (1660‐5540) 1.00 (1.00‐1.00) 0.27
OR and 95% CI were estimated using conditional logistic analysis. P values below 0.05 are marked in bold.
aValues are medians (minimum and maximum).
bPresented in days.
cPresented in grams.
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Maternal microbial infections during pregnancy can affect the
fetus in several ways. Viral infections can cross the placental barrier
or infect the placenta, which can have severe consequences for the
fetus.31-33 Infections can also affect the fetus through a local inflam-
matory response in the placenta or activation of the maternal sys-
temic immune response.31 For instance, toll‐like receptors (TLRs) are
an important part of innate immunity against viruses and the type of
TLR activated is suggested to depend on the mechanism of replica-
tion used by the virus.34 Maternal exposure to farming has been
shown to increase gene expression of certain TLRs in cord blood,17
and increased expression of some TLR genes at birth has been asso-
ciated with a reduced risk of atopy in the offspring.16 There are also
some indications that maternal infections during pregnancy might
affect the placental microbiome,35 that may in turn influence the
microbial composition of the newborn infant's first intestinal dis-
charge (meconium).36 Differential activation of innate immunity or
changes in the composition of early microbiota might be possible
mechanisms behind the findings in our study and offer an interesting
field for future research.
The strengths of this study include the prospective study setting,
availability of paired serum samples taken during pregnancy and the
strict definition of atopic outcome including both IgE sensitization
and a clinically relevant atopic disease. Most importantly, we relied
on serologically confirmed infections. Many infections, including EV
infections, are asymptomatic or cause only mild clinical presenta-
tions, but serological assays are able to capture both symptomatic
and silent infections. There are only a few previous studies with lab-
oratory‐confirmed infections during pregnancy, and to our
F IGURE 1 The proportion (%) of case
and control mothers with an acute EV, IAV
or M. pneumoniae infection during
pregnancy or seropositivity against CMV
or H. pylori. CMV, cytomegalovirus; EV,
enterovirus; H. pylori, Helicobacter pylori;
IAV, influenza A virus; M. pneumoniae,
Mycoplasma pneumoniae
F IGURE 2 The associations between
acute infections during pregnancy (EV, IAV
and M. pneumoniae) or mother's
seropositivity (CMV and H. pylori) and
atopic disease in the offspring. Results are
presented as OR and 95% CI for each
microbe before and after adjusting for
relevant confounding factors, that is,
having older siblings and contact with furry
animals (adj. OR). CMV, cytomegalovirus;
EV, enterovirus; H. pylori, Helicobacter
pylori; IAV, influenza A virus;
M. pneumoniae, Mycoplasma pneumoniae
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knowledge, the microbes included in the present study have not
been studied previously in detail.19-21 In a study by Murphy et al,22
they used PCR to detect viruses (including EVs and IAVs) from nasal
swabs taken from pregnant asthmatic mothers during a symptomatic
upper respiratory infection. They reported that infants born to moth-
ers with nasal swab positive for any of the tested viruses had an
increased risk of atopy as compared to virus negative mothers. How-
ever, numbers of detected viruses were relatively small; for example,
only 3 EVs detected in 42 samples, and therefore, no conclusions
could be drawn about the role of individual viruses. In the present
study, we used systematic serological screening to detect both
symptomatic and asymptomatic infections as well as infections that
did not coincide with the sample draws.
Acute gestational infections were diagnosed by increases in IgG
levels between maternal serum samples taken at the end of the first
trimester and cord blood serum. The time interval between the two
samples was longer than that usually applied in clinical diagnostics,
but it enabled us to capture acute gestational infections as exten-
sively as possible. IgG responses last usually for several months or
years, but it is possible that some infections may have remained
undetectable due to low or short IgG responses. However, this
should have occurred similarly in both case and control groups. We
used cord blood serum as the second sample, since no maternal
serum was taken at delivery. We have previously shown that EV IgG
levels in cord blood sera correlate well with IgG levels in maternal
sera at the time of delivery.37 We did not measure IgM antibodies,
since IgM antibodies do not cross the placenta and IgM responses
do not develop in all EV infections leading to diminished sensitiv-
ity.38
There are some limitations of our study. First, lack of information
on parental history of atopy prevented us from analysing the results
with respect to different genetic backgrounds. Therefore, the possi-
bility that atopic mothers are genetically less susceptible to EV infec-
tions or that there is another immunological or environmental factor
affected by maternal atopy status, cannot be excluded. Secondly, our
study population was selected for type 1 diabetes‐associated HLA
genotypes, which could affect the generalizability of the results.
Although HLA‐DQ region has been linked to asthma, the genetic
backgrounds of IgE sensitization and atopic diseases are highly poly-
morphic with no strong association to HLA‐DQ region.39 Therefore,
we find it unlikely that the HLA selection would substantially influ-
ence our results. Furthermore, the case and control groups were
matched for the type 1 diabetes‐associated HLA genotypes. It
should also be noted that the prevalence of acute EV infections dur-
ing pregnancy was found to be relatively low, being in line with pre-
vious studies.37,40 As atopic diseases are common in childhood, it is
likely that gestational EV infections are not a major risk‐modifying
factor in atopy. However, the observational design of the present
study makes it difficult to estimate the potential size of this effect
on population level reliably. One should also note that even though
the specificity of the current EV antibody assay has been well docu-
mented,41 we cannot completely exclude the possibility that in some
cases, it could have detected antibodies against other viruses than
EVs. Finally, we have not addressed the mechanisms behind the
inverse association between gestational EV infections and atopy, and
therefore, it is possible that EVs are merely a surrogate marker for a
certain kind of environment mediating the effect observed.
In conclusion, our study suggests that maternal EV infections
during pregnancy are inversely associated with atopic disease in the
offspring. Other included microbes causing acute or chronic infec-
tions lacked this association suggesting that microbes differ in their
capability to affect the processes involved in the development of
atopy. This stresses the importance of microbe‐specific identification
of infections when evaluating their role in the pathogenesis of atopy.
Previous research has shown that postnatal infections play a role in
the development of atopy, and our study adds to this knowledge by
suggesting that microbial exposure already in utero might also be of
importance. Thus, addressing the overall effect of gestational and
postnatal infections on the development of atopy is an important
objective for future studies.
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